TSI Group (TSI) announced today the approval of the first and only CFDA (China Food and Drug Administration) Manufacturing License for HMB production in China. TSI’s Jiangyin Pharmaceutical facility, a wholly owned TSI Group company, received this exclusive license to produce HMB for use in Chinese food products.
Additionally, CFDA approved TSI’s HMB for an expanded range of Novel Food categories, such as beverages, chocolates, candies and baked goods, in addition to the existing and approved Chinese HMB markets; Sports Nutrition and Foods for Special Medical Purpose (FSMP, or Medical Foods).
With the two new approvals, TSI is effectively positioned as the market leader and the only HMB manufacturer in China authorized to both produce and sell HMB ingredients domestically to the Chinese food and functional food markets. China is a key market for TSI’s global muscle health growth strategy where TSI’s mission is to deliver muscle health benefits that enhance and maintain consumers healthy and active lifestyles.
TSI’s HMB is widely used in sports nutrition supplements globally to improve muscle health by increasing strength, lean body mass and recovery while reducing muscle damage associated with training and exercise. HMB is also a growing, key functional ingredient for nutritional foods geared towards adult nutrition where it provides proven benefits for improved strength and age-related muscle loss.
"These recent regulatory approvals are significant milestones for all of us at TSI, the door is now wide open for us to deliver TSI’s world class HMB products to one of the fastest growing markets in the world – China. We know HMB can make a difference in people’s daily lives and are excited for the opportunity to positively impact muscle health for millions of Chinese consumers – from athletes of all kinds to aging adults" said Larry Kolb, President, TSI Group.
For more information please contact TSI USA Inc., Alisan Sullivan email@example.com or 1-406-549-9123 ext. 24.